After Shocks with Dr. Milind Desai on the VALOR-HCM trial

NYACC is proud to present the next installment in its After Shocks series, virtual sessions that provide bite-sized recaps of stellar lectures from prominent Cardiology conferences, such as those hosted by ACC, HRS, HFSA, AHA, SCAI and more.
Milind Desai, MD, MBA, FACC, FAHA, FESC, discusses the VALOR-HCM trial, which was a late breaker at ACC.22, with NYACC Chapter President Srihari S. Naidu, MD, FACC, FAHA, FSCAI.
The VALOR-HCM trial showed that mavacamten improved symptoms and significantly reduced eligibility for needing septal reduction therapy among symptomatic patients with obstructive hypertrophic cardiomyopathy who were considering SRT and on maximally tolerated medical therapy.